Synonyms: QPX-7831 | QPX7831
Compound class:
Synthetic organic
Comment: QPX7831 is an orally bioavailable prodrug of xeruborbactam [1].
The chemical structure of QPX7831 is identical to that for the INN xeruborbactam isoboxil (proposed list 132, Feb. 2025). |
|
No information available. |
Summary of Clinical Use ![]() |
Qpex Biopharma are developing an orally administered combination of QPX7831 + β-lactam antibacterial (proposed trademark ORAvance™) as a treatment for infections caused by carbapenem-resistant and Extended Spectrum Beta-Lactamase (ESBL)-producing Enterobacterales. QPX7831 has completed a Phase 1 trial (NCT04578873) to assess safety, tolerability, and pharmacokinetics in healthy participants. Further Phase 1 studies (not yet recruiting, March 2024) will evaluate a combination of QPX7831 and ceftibuten in healthy participants and those with renal impairment (NCT06079775 and NCT06157242). |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT06079775 | P1, DDI & MAD PK and Safety Study of Xeruborbactam Oral Prodrug in Combo With Ceftibuten in Healthy Participants | Phase 1 Interventional | Qpex Biopharma, Inc. | ||
NCT06157242 | PK & Safety Study of Xeruborbactam Oral Prodrug Combined With Ceftibuten in Participants With Renal Impairment | Phase 1 Interventional | Qpex Biopharma, Inc. | ||
NCT04578873 | Phase 1 Oral QPX7831 SAD and MAD in Healthy Adults | Phase 1 Interventional | Qpex Biopharma, Inc. |